These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24952199)

  • 21. Neurotrophins and psychiatric disorders.
    Castrén E
    Handb Exp Pharmacol; 2014; 220():461-79. PubMed ID: 24668483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Where do you think you are going? The NMDA-D1 receptor trap.
    Cepeda C; Levine MS
    Sci STKE; 2006 May; 2006(333):pe20. PubMed ID: 16670371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mental illness, synapses and the brain--behavioral disorders by a system of molecules within a system of neurons?
    Tretter F
    Pharmacopsychiatry; 2010 May; 43 Suppl 1():S9-S20. PubMed ID: 20486054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the ADHD-susceptibility gene CDH13 on development and function of brain networks.
    Rivero O; Sich S; Popp S; Schmitt A; Franke B; Lesch KP
    Eur Neuropsychopharmacol; 2013 Jun; 23(6):492-507. PubMed ID: 22795700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a high-throughput AlphaScreen assay for modulators of synapsin I phosphorylation in primary neurons.
    Chan B; Cottrell JR; Li B; Larson KC; Ashford CJ; Levenson JM; Laeng P; Gerber DJ; Song J
    J Biomol Screen; 2014 Feb; 19(2):205-14. PubMed ID: 24088370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.
    Ye N; Neumeyer JL; Baldessarini RJ; Zhen X; Zhang A
    Chem Rev; 2013 May; 113(5):PR123-78. PubMed ID: 23464812
    [No Abstract]   [Full Text] [Related]  

  • 27. Proteomic and Microscopic Strategies towards the Analysis of the Cytoskeletal Networks in Major Neuropsychiatric Disorders.
    Coumans JV; Palanisamy SK; McFarlane J; Moens PD
    Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27104521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges in Neuropharmacology.
    Cascorbi I
    Clin Pharmacol Ther; 2019 May; 105(5):1050-1053. PubMed ID: 30986334
    [No Abstract]   [Full Text] [Related]  

  • 29. [GABA A/benzodiazepine receptor. New knowledge may generate new possibilities].
    Litton JE; Hall H
    Lakartidningen; 1993 Mar; 90(9):805-11. PubMed ID: 8383258
    [No Abstract]   [Full Text] [Related]  

  • 30. Neurotrophins and schizophrenia.
    Buckley PF; Mahadik S; Pillai A; Terry A
    Schizophr Res; 2007 Aug; 94(1-3):1-11. PubMed ID: 17524622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The neurotrophin family of neurotrophic factors: an overview.
    Skaper SD
    Methods Mol Biol; 2012; 846():1-12. PubMed ID: 22367796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity.
    Ciani L; Salinas PC
    Nat Rev Neurosci; 2005 May; 6(5):351-62. PubMed ID: 15832199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychiatric disorders biochemical pathways unraveled by human brain proteomics.
    Saia-Cereda VM; Cassoli JS; Martins-de-Souza D; Nascimento JM
    Eur Arch Psychiatry Clin Neurosci; 2017 Feb; 267(1):3-17. PubMed ID: 27377417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signaling mechanisms that coordinate the development and maintenance of dendritic fields.
    Emoto K
    Curr Opin Neurobiol; 2012 Oct; 22(5):805-11. PubMed ID: 22575709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular pathways regulating cytoskeletal organization and morphological changes in migrating neurons.
    Kawauchi T; Hoshino M
    Dev Neurosci; 2008; 30(1-3):36-46. PubMed ID: 18075253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroproteomics: understanding the molecular organization and complexity of the brain.
    Bayés A; Grant SG
    Nat Rev Neurosci; 2009 Sep; 10(9):635-46. PubMed ID: 19693028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders.
    Esteban S; García-Sevilla JA
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):78-87. PubMed ID: 22133541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders.
    Bhattacharya A; Ceusters M
    Neuropsychopharmacology; 2020 Jan; 45(1):234-235. PubMed ID: 31477815
    [No Abstract]   [Full Text] [Related]  

  • 39. Redox Modulations, Antioxidants, and Neuropsychiatric Disorders.
    Fraunberger EA; Scola G; Laliberté VL; Duong A; Andreazza AC
    Oxid Med Cell Longev; 2016; 2016():4729192. PubMed ID: 26640614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technological advances for deciphering the complexity of psychiatric disorders: merging proteomics with cell biology.
    Wesseling H; Guest PC; Lago SG; Bahn S
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1327-41. PubMed ID: 24524332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.